ArticleLung India : official organ of Indian Chest Society2026
A prospective observational study to evaluate the prevalence of severe asthma among subjects with difficult-to-treat asthma at a tertiary care center in North India.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere asthma accounts for disproportionate asthma-related morbidity, mortality, and healthcare costs, yet prospective data on its prevalence remain limited, particularly for developing countries. We aimed to determine the prevalence of severe asthma among subjects with difficult-to-treat asthma at a tertiary care center in North India.
methodsBetween January and December 2023, we prospectively enrolled consecutive adults with difficult-to-treat asthma that remained uncontrolled despite treatment with medium- or high-dose inhaled corticosteroids-long-acting beta-agonist (ICS-LABA) or required high-dose ICS-LABA to maintain good control. All subjects underwent systematic evaluation, including diagnosis confirmation, assessment of inhaler technique and adherence, comorbidity screening, and treatment optimization, with reassessment after 3-6 months. We diagnosed severe asthma (uncontrolled despite high-dose ICS-LABA or required high-dose ICS-LABA to maintain good control) after addressing all modifiable factors and assessed type 2 (T2)-targeted biological therapy eligibility.
resultsAmong 240 subjects (mean age 47.4 ± 14.9 years; 68.8% female), we identified modifiable factors in 218 (90.8%), including suboptimal therapy (74.2%), poor adherence (64.2%), and incorrect technique (58.8%). Following interventions, 154 completed reassessment; 102 (66.2%) no longer met severe asthma criteria. Overall, 67 subjects had severe asthma (27.9%; 95% CI: 22.4-33.9%). Among them, 66.7% had blood eosinophils ≥150 cells/µL, and 68.7% met criteria for T2-targeted biological therapy.
conclusionApproximately one-quarter of subjects with difficult-to-treat asthma have confirmed severe asthma after systematic assessment. A significant proportion improve with targeted interventions, emphasizing the importance of comprehensive evaluation. Most patients with confirmed severe asthma are candidates for T2-targeted biologicals, highlighting the need for structured assessment protocols and improved access to biological therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.